Dunad Therapeutics develops targeted protein degradation therapies using proprietary tunable covalent chemistry to selectively eliminate disease-causing proteins. This approach aims to provide durable treatment options for diseases driven by specific protein dysfunctions, enhancing therapeutic efficacy and patient outcomes.
Funding
$24M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are driven by the dysfunction of specific proteins within the body. Traditional therapeutic approaches often struggle to selectively and durably target these disease-causing proteins, leading to limited efficacy and potential side effects.
Solution
Dunad Therapeutics is developing a new class of medicines based on targeted protein degradation. Their approach utilizes proprietary, tunable covalent chemistry to design molecules that selectively eliminate disease-driving proteins. By covalently binding to target proteins, Dunad's therapies trigger the body's natural degradation pathways, leading to the removal of the dysfunctional protein and a potential durable therapeutic effect. This method aims to provide more effective and precise treatments for diseases caused by specific protein dysfunctions.
Target Audience
The primary target audience includes patients suffering from diseases driven by specific protein dysfunctions, as well as pharmaceutical companies seeking novel therapeutic approaches.
Features
- Proprietary tunable covalent chemistry platform for selective protein degradation
- Design of molecules that covalently bind to target disease-driving proteins
- Leveraging the body's natural degradation pathways for protein elimination
- Potential for durable therapeutic effects through sustained protein reduction